Literature DB >> 22810499

Genetic variants of EGFR (142285G>A) and ESR1 (2014G>A) gene polymorphisms and risk of breast cancer.

Ranbir Chander Sobti1, Marjan Askari, Mohsen Nikbakht, Neha Singh, Suresh C Sharma, Abayneh Munshea Abitew.   

Abstract

Breast cancer is one of the most common cancers in women worldwide. The estrogen receptor alpha (ESR1) and epidermal growth factor receptor (EGFR) have been known to play a vital role in development and progression of breast cancer. The aim of the present study was to determine the relationship, if any, between genetic polymorphism in (ESR1) 2014G>A (T594T) and (EGFR) 142285G>A (R521K) with risk of breast cancer and the prognosis in a heterogeneous North Indian population that is known for its diverse ethnicity. A case-control study in a total of 300 individuals comprising of 150 breast cancer patients and 150 normal controls was performed. PCR-RFLP was employed for genotyping. The G/A heterozygous genotype EGFR R521K, was slightly higher in cases (56.7 %) than in controls (48.3 %) (P = 0.20). The results indicated that EGFR polymorphism does not show any significant association with breast cancer in this population. On the other hand, the mutant A/A genotype ESR1 codon 594, showed a 6.4-folds risk for breast cancer and this association was highly significant (P = 0.00) as compared to wild GG genotype, the heterozygous G/A genotype also showed a significant association with disease (P = 0.00, OR = 2.03). In addition, the frequency of A allele was also higher in cases (36 %) than in controls (19 %) and a highly significant difference was observed with wild G allele (63.3 % in cases and 6.6 % in controls). This clearly indicates that there appears to be an influence of ESR1 codon 594 genotypes on genetic susceptibility to breast cancer. Further a significantly higher risk was observed in individuals who had diabetes {OR = 3.04 (1.68-5.50), P = 0.00} and females with ESR polymorphism in pre-menopause patients that had undergone menopause above the age of 50 years {OR = 3.58 (1.86-6.90), P < 0.05}. The different ethnic backgrounds and geographical locations have complimented the present genotypic analysis and have highlighted the influence of ethnicity, race and geographic location in genetic predisposition to breast cancer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22810499     DOI: 10.1007/s11010-012-1384-x

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  47 in total

Review 1.  Low penetrance genes associated with increased risk for breast cancer.

Authors:  B L Weber; K L Nathanson
Journal:  Eur J Cancer       Date:  2000-06       Impact factor: 9.162

Review 2.  Estrogen receptor: current understanding of its activation and modulation.

Authors:  C K Osborne; R Schiff; S A Fuqua; J Shou
Journal:  Clin Cancer Res       Date:  2001-12       Impact factor: 12.531

3.  Gene polymorphisms of epidermal growth factor receptor and its downstream effector, interleukin-8, predict oxaliplatin efficacy in patients with advanced colorectal cancer.

Authors:  Wu Zhang; Jan Stoehlmacher; David J Park; Dongyun Yang; Erin Borchard; Ji Gil; Denice D Tsao-Wei; Jim Yun; Michael Gordon; Oliver A Press; Katrin Rhodes; Susan Groshen; Heinz-Josef Lenz
Journal:  Clin Colorectal Cancer       Date:  2005-07       Impact factor: 4.481

4.  Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas.

Authors:  DuyKhanh Pham; Mark G Kris; Gregory J Riely; Inderpal S Sarkaria; Tiffani McDonough; Shaokun Chuai; Ennapadam S Venkatraman; Vincent A Miller; Marc Ladanyi; William Pao; Richard K Wilson; Bhuvanesh Singh; Valerie W Rusch
Journal:  J Clin Oncol       Date:  2006-02-27       Impact factor: 44.544

5.  Nuclear localization of EGF receptor and its potential new role as a transcription factor.

Authors:  S Y Lin; K Makino; W Xia; A Matin; Y Wen; K Y Kwong; L Bourguignon; M C Hung
Journal:  Nat Cell Biol       Date:  2001-09       Impact factor: 28.824

6.  Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.

Authors:  Federico Cappuzzo; Fred R Hirsch; Elisa Rossi; Stefania Bartolini; Giovanni L Ceresoli; Lynne Bemis; Jerry Haney; Samir Witta; Kathleen Danenberg; Irene Domenichini; Vienna Ludovini; Elisabetta Magrini; Vanesa Gregorc; Claudio Doglioni; Angelo Sidoni; Maurizio Tonato; Wilbur A Franklin; Lucio Crino; Paul A Bunn; Marileila Varella-Garcia
Journal:  J Natl Cancer Inst       Date:  2005-05-04       Impact factor: 13.506

Review 7.  Estrogens in the causation of breast, endometrial and ovarian cancers - evidence and hypotheses from epidemiological findings.

Authors:  I Persson
Journal:  J Steroid Biochem Mol Biol       Date:  2000-11-30       Impact factor: 4.292

8.  EGFR pathway polymorphisms and bladder cancer susceptibility and prognosis.

Authors:  Rebecca A Mason; Elaine V Morlock; Margaret R Karagas; Karl T Kelsey; Carmen J Marsit; Alan R Schned; Angeline S Andrew
Journal:  Carcinogenesis       Date:  2009-04-16       Impact factor: 4.944

9.  Estrogen receptor codon 594 and HER2 codon 655 polymorphisms and breast cancer risk.

Authors:  Elif Akisik; Nejat Dalay
Journal:  Exp Mol Pathol       Date:  2004-06       Impact factor: 3.362

10.  Structure and localization of genes encoding aberrant and normal epidermal growth factor receptor RNAs from A431 human carcinoma cells.

Authors:  G T Merlino; S Ishii; J Whang-Peng; T Knutsen; Y H Xu; A J Clark; R H Stratton; R K Wilson; D P Ma; B A Roe; John Hunts; Nobuyoshi Shimizu; Ira Pastan
Journal:  Mol Cell Biol       Date:  1985-07       Impact factor: 4.272

View more
  4 in total

1.  Epidermal growth factor receptor (EGFR) polymorphisms and breast cancer among Hispanic and non-Hispanic white women: the Breast Cancer Health Disparities Study.

Authors:  Avonne E Connor; Richard N Baumgartner; Kathy B Baumgartner; Christina M Pinkston; Esther M John; Gabriela Torres-Mejía; Lisa M Hines; Anna R Giuliano; Roger K Wolff; Martha L Slattery
Journal:  Int J Mol Epidemiol Genet       Date:  2013-11-28

2.  The polymorphism of EGFR 142285G > A exerts no risk effect on breast cancer.

Authors:  Qingcun Zheng; Ruiying Chen; Liqin Luan; Junrui Li; Suling Gao
Journal:  Tumour Biol       Date:  2013-10-28

3.  The distribution pattern of ERα expression, ESR1 genetic variation and expression of growth factor receptors: association with breast cancer prognosis in Russian patients treated with adjuvant tamoxifen.

Authors:  Nataliya Babyshkina; Sergey Vtorushin; Marina Zavyalova; Stanislav Patalyak; Tatyana Dronova; Nikolay Litviakov; Elena Slonimskaya; Julia Kzhyshkowska; Nadejda Cherdyntseva; Evgeny Choynzonov
Journal:  Clin Exp Med       Date:  2016-05-25       Impact factor: 3.984

4.  A Meta-Analysis on the Relations between EGFR R521K Polymorphism and Risk of Cancer.

Authors:  Yinsheng Wang; Lidan Zha; Dan Liao; Xiaozhi Li
Journal:  Int J Genomics       Date:  2014-10-21       Impact factor: 2.326

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.